| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.12 | 0.009 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.009 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.097 | 0.01 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.01 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |